
    
      This is a Phase 1, safety and efficacy study of XT-150 in adult participants experiencing
      back pain due to inflammation of the facet joint osteoarthritis (FJOA) and who are eligible
      for intra-synovial glucocorticoid injection, or radiofrequency ablation of medial branches of
      the primary dorsal ramus of the exiting nerve root, which innervates the adjacent facet
      joints.
    
  